DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway

Liana Adam, F. Anthony San Lucas, Richard Fowler, Yao Yu, Wenhui Wu, Yulun Liu, Huamin Wang, David Menter, Michael T. Tetzlaff, Joe Ensor, Ganiraju Manyam, Stefan T. Arold, Chad Huff, Scott Kopetz, Paul Scheet, Michael J. Overman

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

PURPOSE: Little is known about the genetic alterations characteristic of small bowel adenocarcinoma (SBA). Our purpose was to identify targetable alterations and develop experimental models of this disease.Experimental Design: Whole-exome sequencing (WES) was completed on 17 SBA patient samples and targeted-exome sequencing (TES) on 27 samples to confirm relevant driver mutations. Two SBA models with ERBB2 kinase activating mutations were tested for sensitivity to anti-ERBB2 agents in vivo and in vitro. Biochemical changes were measured by reverse-phase protein arrays. RESULTS: WES identified somatic mutations in 4 canonical pathways (WNT, ERBB2, STAT3, and chromatin remodeling), which were validated in the TES cohort. Although APC mutations were present in only 23% of samples, additional WNT-related alterations were seen in 12%. ERBB2 mutations and amplifications were present in 23% of samples. Patients with alterations in the ERBB2 signaling cascade (64%) demonstrated worse clinical outcomes (median survival 70.3 months vs. 109 months; log-rank HR = 2.4, P = 0.03). Two ERBB2-mutated (V842I and Y803H) cell lines were generated from SBA patient samples. Both demonstrated high sensitivity to ERBB2 inhibitor dacomitinib (IC50 < 2.5 nmol/L). In xenografts derived from these samples, treatment with dacomitinib reduced tumor growth by 39% and 59%, respectively, whereas it had no effect in an SBA wild-type ERBB2 model. CONCLUSIONS: The in vitro and in vivo models of SBA developed here provide a valuable resource for understanding targetable mutations in this disease. Our findings support clinical efforts to target activating ERBB2 mutations in patients with SBA that harbor these alterations.

Original languageEnglish (US)
Pages (from-to)641-651
Number of pages11
JournalClinical cancer research : an official journal of the American Association for Cancer Research
Volume25
Issue number2
DOIs
StatePublished - Jan 15 2019
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway'. Together they form a unique fingerprint.

  • Cite this

    Adam, L., San Lucas, F. A., Fowler, R., Yu, Y., Wu, W., Liu, Y., Wang, H., Menter, D., Tetzlaff, M. T., Ensor, J., Manyam, G., Arold, S. T., Huff, C., Kopetz, S., Scheet, P., & Overman, M. J. (2019). DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway. Clinical cancer research : an official journal of the American Association for Cancer Research, 25(2), 641-651. https://doi.org/10.1158/1078-0432.CCR-18-1480